Skip to content
type1.science

Senseonics Eversense 365

Senseonics / Ascensia Diabetes Care

The world's first one-year implantable CGM — a fluorescence-based sensor placed under the upper-arm skin by a clinician, paired with a removable rechargeable transmitter. Just one insertion a year and roughly weekly calibration, with an 8.8% MARD and iCGM clearance for automated insulin delivery.

Available nowRegulator-approvedcgmimplantable

The scorecard

Accuracy82

Overall MARD 8.8% across a full year in the ENHANCE pivotal study (110 adults) — solidly accurate and meeting iCGM special controls, though a touch behind the best 8.0–9.1% disposable sensors at their peak.[1]

Low lag60

Reads interstitial fluid like every CGM, so the ~5–10 min physiological lag remains; but its deep-tissue placement gives "virtually no compression lows," so far fewer false overnight low alerts.[5]

Interoperability55

iCGM-classified and now live in automated insulin delivery with the Sequel twiist pump (first AID partner, 2026); streams to iOS/Android and shows on Apple Watch as a secondary display. No open-source loop support and only one AID partner so far.[9]

Sensor lifespan100

A full 365 days from a single sensor — by far the longest-wearing CGM in existence; 90% of sensors survived the full year in ENHANCE.[1]

No calibration35

Not factory-calibrated. Four fingersticks at start, then daily for ~13 days, then roughly one fingerstick per week for the rest of the year — far less than older Eversense but still not calibration-free.[6]

Alerts & prediction85

On-body vibration alerts (high/low/out-of-range) you feel even without your phone — unique among CGMs — plus both high and low predictive alerts; 96.6% confirmed alert detection at 70 mg/dL.[1]

Form factor45

Requires a quick in-office insertion and removal by a clinician (minor procedure), and a daily adhesive change for the on-skin transmitter, which must be recharged. Trade-off for nothing to insert yourself for a year and a removable transmitter.[6]

Ketone sensing0

Glucose only — no ketone or multi-analyte sensing.[5]

Access & cost40

Available in the US (launched Q4 2024) and now CE-marked for the EU (Jan 2026) with rollout to Germany/Italy/Spain/Sweden underway; broadly covered by US commercial plans and Medicare for insulin users (a patient-assistance program can keep annual out-of-pocket cost low), but not Medicaid, and requires a clinician trained to insert it.[12]

The full picture

The Eversense 365 is unlike any other glucose sensor: instead of a patch you stick on and replace every week or two, it is a small fluorescence-based sensor — under three-quarters of an inch long — that a trained clinician slides just under the skin of your upper arm in a few-minute in-office procedure, where it stays and reads glucose for a full year.12 It is the world's first one-year CGM.1 A separate removable, rechargeable transmitter sits on the skin over the sensor (held by a gentle silicone adhesive you change daily), powers the sensor, and sends a reading to your phone every five minutes.3 Because the transmitter comes off, you can take it off to shower or charge it without wasting the sensor.3

How accurate is it? In the ENHANCE pivotal study of 110 adults, the Eversense 365 had an overall MARD of 8.8% across the entire year — meaning readings landed, on average, within about 8.8% of lab glucose — while needing only about one calibration per week.4 According to PubMed, ENHANCE also reported a 96.6% confirmed alert-detection rate at 70 mg/dL (low) and 97.9% at 180 mg/dL (high), and 90% of sensors survived the full 365 days (DOI).4 In the low range specifically, the manufacturer reports a mean absolute difference of 7.7 mg/dL and detection of 91% of lows at 60 mg/dL.5 A real strength of deep-tissue placement: virtually no "compression lows," so far fewer false alarms when you lie on it overnight.5

Wear, warm-up and calibration. One insertion lasts up to 12 months.2 After the sensor is linked to the transmitter there is a 24-hour warm-up with no readings, then four fingerstick calibrations spaced 2–12 hours apart before glucose displays.67 You then calibrate daily for about the first 13 days, after which it drops to roughly once a week for the rest of the year — the lightest calibration burden of any Eversense generation, though still not fully calibration-free like Dexcom or Libre.15

Alerts. Uniquely, the transmitter gives on-body vibration alerts for highs, lows and out-of-range — you feel them on your arm even if your phone is in another room — and the app has both high and low predictive alerts to warn you before you cross a threshold.57

What it works with. It is iCGM-classified, and in 2026 it became the first implantable CGM used in automated insulin delivery, paired with the Sequel twiist pump.89 Data goes to iPhone and Android, with a snapshot on Apple Watch as a secondary display.9 There is no ketone sensing and no open-source/DIY loop support.5

Who it's for, and where. Cleared for adults 18+ with type 1 or type 2 diabetes; not for use in pregnancy.27 It is sold in the US (launched late 2024) and is now CE-marked in the EU (January 2026), with rollout to Germany, Italy, Spain and Sweden underway.10 Most US commercial plans and Medicare cover it for people on insulin (Medicaid does not), and the PASS assistance program can keep commercial out-of-pocket low for a full year, not counting the insertion/removal procedures.11

What's coming. The line has marched from 90 to 180 to 365 days,12 and the near-term direction is wider AID integration — twiist is the first pump partner, with the company signalling more to come — plus the European launch now opening up.810

References

  1. Senseonics / Ascensia Diabetes Care. Eversense 365 Receives FDA Clearance: The World's First One Year CGM (press release, 17 Sep 2024). https://www.globenewswire.com/news-release/2024/09/17/2947270/0/en/Eversense-365-Receives-FDA-Clearance-The-World-s-First-One-Year-CGM.html ↩ ↩2 ↩3

  2. U.S. FDA. 510(k) K241335 — Eversense 365 Continuous Glucose Monitoring System (applicant Senseonics, Inc.; cleared as integrated CGM; adults 18+, up to 1 year; decision Sept 2024). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K241335 ↩ ↩2 ↩3

  3. Senseonics. Get to Know Your Eversense 365 Smart Transmitter (removable, rechargeable, water-resistant; daily silicone adhesive; recharge ~5 min every 1–2 days). https://www.eversensecgm.com/resources-365/smart-transmitter/ ↩ ↩2

  4. Bailey TS, Liljenquist DR, Denham DS, et al. Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense CGM System: The ENHANCE Study. Diabetes Technology & Therapeutics 2025;27(5):407–411 (per PubMed). PMID 39869118. DOI. https://pubmed.ncbi.nlm.nih.gov/39869118/ ↩ ↩2

  5. Senseonics / Ascensia. Eversense 365 — Complete CGM System for Healthcare Providers (90% 365-day survival; low-range MAD 7.7 mg/dL; 91% detection of lows at 60 mg/dL; on-body vibration alerts; virtually no compression lows; weekly calibration after day 13). https://provider.eversensecgm.com/eversense-365/ ↩ ↩2 ↩3 ↩4 ↩5

  6. Senseonics. Eversense 365 Sensor Placement & Calibration (24-hour warm-up after linking the transmitter, then 4 fingerstick calibrations 2–12 h apart). https://www.eversensecgm.com/sensor-placement/ ↩

  7. American Diabetes Association. Eversense 365 CGM System — Consumer Guide (MARD 8.8%; 24-hour warm-up; calibration schedule; submersible 1 m/30 min; predictive + on-body alerts; iPhone/Android + Apple Watch; adults 18+, not in pregnancy). https://consumerguide.diabetes.org/products/cgms/eversense-365-cgm-system ↩ ↩2 ↩3

  8. Drug Delivery Business News. Senseonics launches Eversense 365 CGM with Sequel twiist pump — twiist is the first AID system compatible with Eversense 365 (Jan 2026). https://www.drugdeliverybusiness.com/senseonics-sequel-launch-eversense-365-twiist/ ↩ ↩2

  9. Senseonics / Ascensia. Eversense 365: CGM with Insulin Pump Integration (only one-year CGM cleared for AID, starting with the twiist system; Apple Watch as secondary display). https://www.eversensecgm.com/partners/ ↩ ↩2

  10. Drug Delivery Business News. Senseonics wins CE mark for Eversense 365 year-long CGM (CE mark 29 Jan 2026; EU launch planned in Germany, Italy, Spain, Sweden). https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ ↩ ↩2

  11. Senseonics / Ascensia. Understanding CGM Cost: Insurance Coverage & Prices for Eversense 365 (covered by most US commercial plans and Medicare for insulin users; not Medicaid; PASS program keeps annual out-of-pocket low for the commercially insured). https://www.eversensecgm.com/cost-and-insurance/ ↩

  12. Garg SK, Liljenquist D, Bode B, et al. Accuracy and Safety of the Up-to-180-Day Implantable Eversense CGM System: The PROMISE Study. Diabetes Technology & Therapeutics 2022;24(2):84–92 (per PubMed). PMID 34515521. DOI. https://pubmed.ncbi.nlm.nih.gov/34515521/ ↩

What's next for this

  • →EU rollout underway (Germany, Italy, Spain, Sweden) after the Jan 2026 CE mark; additional AID partners beyond the twiist pump expected · 2026

Sources

  1. [1]Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense CGM System: The ENHANCE Study · peer-reviewed · 2025-01-27 — Bailey TS, Liljenquist DR, Denham DS, et al. Diabetes Technol Ther 2025;27(5):407-411. DOI 10.1089/dia.2024.0592. PMID 39869118 (per PubMed). n=110 adults implanted; overall MARD 8.8% with primarily one calibration/week; confirmed alert detection 96.6% at 70 mg/dL and 97.9% at 180 mg/dL; 90% sensor survival at 365 days; iCGM special controls met; no related serious adverse events.
  2. [2]Accuracy and Safety of the Up-to-180-Day Implantable Eversense CGM System: The PROMISE Study · peer-reviewed · 2021-09-09 — Garg SK, Liljenquist D, Bode B, et al. Diabetes Technol Ther 2022;24(2):84-92. DOI 10.1089/dia.2021.0182. PMID 34515521 (per PubMed). Prior 180-day generation; SBA sensor MARD 8.5%, 90% survival to 180 days — the platform the 365 builds on.
  3. [3]510(k) K241335 — Eversense 365 Continuous Glucose Monitoring System · regulatory · 2024-09-16 — FDA 510(k) clearance, applicant Senseonics, Incorporated; cleared as an integrated CGM (iCGM). Indicated for adults 18+ with diabetes for up to 1 year, to replace fingerstick measurements for treatment decisions.
  4. [4]Eversense 365 Receives FDA Clearance: The World's First One Year CGM · manufacturer · 2024-09-17 — Senseonics / Ascensia press release; FDA clearance 17 Sep 2024; weekly calibration after day 14; iCGM for AID; US launch early Q4 2024.
  5. [5]Eversense 365 — Complete CGM System for Healthcare Providers · manufacturer — Clinician-facing specs: 90% 365-day sensor survival; low-range MAD 7.7 mg/dL; 91% detection of lows at 60 mg/dL; on-body vibration alerts; virtually no compression lows; one transmitter/year; weekly calibration after day 13.
  6. [6]Eversense 365 CGM System — ADA Consumer Guide · news — American Diabetes Association consumer guide: MARD 8.8%; 365-day wear; 24-hour (1440-min) warm-up; 4 initial fingerstick calibrations then daily for 13 days then weekly; submersible to 1 m for 30 min; predictive and on-body vibe alerts; iPhone/Android + Apple Watch; adults 18+, not in pregnancy.
  7. [7]Eversense 365 Quick Reference / Calibration & Warm-Up · manufacturer — 24-hour warm-up after the sensor is linked to the transmitter; then 4 fingerstick calibrations 2–12 h apart in the initialization phase before readings display.
  8. [8]Get to Know Your Eversense 365 Smart Transmitter · manufacturer — Removable, rechargeable, water-resistant on-skin transmitter held by a daily silicone adhesive; charged for ~5 minutes every 1–2 days.
  9. [9]Senseonics launches Eversense 365 CGM with Sequel twiist pump · news — Jan 2026 — twiist by Sequel Med Tech is the first AID system compatible with Eversense 365, making it the first implantable CGM usable in automated insulin delivery.
  10. [10]Eversense 365: CGM with Insulin Pump Integration · manufacturer — Describes Eversense 365 as the only one-year CGM cleared for AID, starting with the twiist AID system; Apple Watch as a secondary display.
  11. [11]Senseonics wins CE mark for Eversense 365 year-long CGM · news — CE mark granted 29 Jan 2026; planned EU launch in Germany, Italy, Spain and Sweden; cited as expanding the addressable market by 30M+ EU patients.
  12. [12]Understanding CGM Cost: Insurance Coverage & Prices for Eversense 365 · manufacturer — Covered by most US commercial plans and Medicare for insulin users; not Medicaid/Medi-Cal; PASS patient-assistance program can keep commercial out-of-pocket low for a full year (excludes insertion/removal procedures).